High-dose statin therapy with rosuvastatin reduces small dense LDL and MDA-LDL: The Standard versus high-dose therApy with Rosuvastatin for lipiD lowering (SARD) trial. Issue 4 (April 2016)

• Record Type: Journal Article
• Authors: Nishikido, Toshiyuki; Oyama, Jun-ichi; Keida, Takehiko; Ohira, Hiroshi; Node, Koichi
• Is Part Of: Journal of cardiology. Volume 67:Issue 4(2016:Apr.)
• Page Start: 340
• Page End: 346
• Publication Date: 2016-04
• Subjects: HMG-CoA reductase inhibitor -- Small-dense low-density lipoprotein -- Malondialdehyde -- High-sensitivity C-reactive protein -- High-dose statin therapy; Cardiology -- Periodicals; 616.12
• DOI: 10.1016/j.jjcc.2015.05.017
• Languages: English
• ISSNs: 0914-5087

Abstract

Abstract: Background: Cardiovascular events (CV) continue to occur due to residual risks in high-risk patients in spite of substantial reductions in the low-density lipoprotein cholesterol (LDL) with statins. It has been reported that the small-dense LDL (sd-LDL) components of high atherogenic particles are associated with an increased risk of CV, more than large buoyant LDL. However, there are few reports regarding the effects of high-dose statin therapy in improving atherogenic lipoproteins. Methods and results: In this prospective, randomized, open-label, multicenter study, a total of 111 high-risk patients were randomly assigned to two groups. In the high-dose therapy group, 58 patients were administered 5 mg of rosuvastatin per day for four weeks, after which the dose was titrated to 10 mg for the following eight weeks. In the low-dose therapy group, 53 patients were given 2.5 mg for 12 weeks. We evaluated the lipid profiles, including the levels of sd-LDL, malondialdehyde-modified LDL-cholesterol (C) (MDA-LDL) as oxidized-LDL, and remnant-like particle-cholesterol. The LDL-C, non-high-density lipoprotein (HDL), and LDL-C/HDL-C ratio were decreased in the high-dose therapy group ( p < 0.01). Moreover, the sd-LDL and MDA-LDL levels were significantly reduced in the high-dose therapy group ( p < 0.05). There were no serious adverse events in either group. Conclusions: High-dose statin therapy significantly reduced the sd-LDL and MDA-LDL components of atherosclerotic lipoproteins without adverse events in comparison with low-dose statin therapy.